CDT Equity Receives Nasdaq Notice Over Late Filing
TipRanks (Thu, 28-May 6:38 PM ET)
CDT Equity receives Nasdaq notice over delayed quarterly filing
Seeking Alpha News (Thu, 28-May 4:22 PM ET)
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
Globe Newswire (Thu, 28-May 4:15 PM ET)
CDT Announces Canadian Patent for AZD5904 in Male Infertility
Globe Newswire (Wed, 27-May 8:00 AM ET)
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
Globe Newswire (Thu, 7-May 8:30 AM ET)
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
Globe Newswire (Wed, 6-May 8:30 AM ET)
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
Globe Newswire (Thu, 16-Apr 8:30 AM ET)
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
Globe Newswire (Tue, 7-Apr 8:30 AM ET)
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
Globe Newswire (Thu, 26-Mar 8:30 AM ET)
CDT Equity Inc. Announces Reverse Stock Split
Globe Newswire (Wed, 25-Mar 8:00 AM ET)
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
CDT Equity trades on the NASDAQ stock market under the symbol CDT.
As of June 1, 2026, CDT stock price declined to $0.89 with 1,256,920 million shares trading.
CDT has a beta of 1.28, meaning it tends to be more sensitive to market movements. CDT has a correlation of 0.01 to the broad based SPY ETF.
CDT has a market cap of $4.35 million. This is considered a Sub-Micro Cap stock.
CDT has underperformed the market in the last year with a price return of -99.9% while the SPY ETF gained +29.8%. CDT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -94.8% and -48.1%, respectively, while the SPY returned +10.8% and +2.6%, respectively.
CDT support price is $.92 and resistance is $1.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDT shares will trade within this expected range on the day.